分组1 - Long Cast Advisers reported a cumulative net return increase of 1% in Q4 2025, with a flat cumulative portfolio return for the year, and a total cumulative return of 271% net of fees since inception in November 2015 [1] - The firm managed 28 SMA accounts with an AUM of $12 million by year-end 2025, focusing on small companies and demonstrating varied returns relative to the broader market over a 10-year performance history [1] - The portfolio's top five holdings provide insights into key selections for 2025, indicating a strategic focus on specific stocks [1] 分组2 - Cross Country Healthcare, Inc. (NASDAQ:CCRN) was highlighted as a significant stock, with a market capitalization of $318.34 million and a one-month return of 23.02%, despite a 52-week loss of 37.94% [2] - The company specializes in talent management services for healthcare clients, particularly in nurse and allied staffing, and physician staffing [2] - Long Cast Advisers made significant purchases of Cross Country Healthcare, Inc. at an average price of $8.24 per share, revisiting the stock after previously selling it during negative COVID comparisons [3] - Cross Country Healthcare, Inc. has $99 million in net cash and no debt, with a pro forma enterprise value of $140 million after receiving a $20 million termination payment from a failed acquisition [3]

Financial Performance - For the year ended December 31, 2025, consolidated revenue decreased by 21.6% year-over-year to $1.1 billion, primarily due to volume declines in the Nurse and Allied Staffing and Physician Staffing segments [175]. - The net loss attributable to common stockholders for the year ended December 31, 2025 was $94.9 million, compared to a net loss of $14.6 million for the year ended December 31, 2024, representing an increase in losses of 551.6% [175][187]. - Total revenues from services decreased by $289.7 million, or 21.6%, to $1,054.3 million for the year ended December 31, 2025, compared to $1,344.0 million for 2024 [200][202]. - Nurse and Allied Staffing revenue decreased by $282.6 million, or 24.7%, to $862.8 million for the year ended December 31, 2025, primarily due to a decline in billable hours [202]. - Contribution income for Nurse and Allied Staffing decreased by $14.7 million, or 20.2%, to $57.9 million for the year ended December 31, 2025, with a contribution margin of 6.7% [203]. Expenses and Costs - Direct operating expenses decreased by 21.4% to $840.7 million for the year ended December 31, 2025, as a result of revenue decreases [189]. - Selling, general and administrative expenses decreased by 14.0% to $200.7 million for the year ended December 31, 2025, primarily due to decreases in compensation and benefit expenses [189]. - The Company recorded executive transition severance costs of $6.0 million related to the former Chief Executive Officer's separation from the Company in December 2025 [178]. - Corporate overhead decreased to $60.8 million for the year ended December 31, 2025, from $68.5 million in 2024, representing 5.8% of consolidated revenue [207]. Cash Flow and Liquidity - Cash and cash equivalents totaled $108.7 million as of December 31, 2025, with cash flow provided by operating activities amounting to $48.3 million for the year [179]. - Net cash provided by operating activities decreased by $71.8 million to $48.3 million for the year ended December 31, 2025, compared to $120.1 million for 2024 [212]. - As of December 31, 2025, the company reported $108.7 million in cash and cash equivalents, with working capital increasing by $1.2 million to $215.8 million [208]. - As of December 31, 2025, the borrowing base availability under the ABL was $114.6 million, with no borrowings drawn and $96.3 million available net of $18.3 million of letters of credit outstanding [219]. Impairments and Taxation - During the fourth quarter of 2025, the Company recorded a non-cash goodwill impairment charge of $77.9 million related to its Nurse and Allied and Physician Staffing segments [176]. - Non-cash impairment charges totaled $77.9 million for the year ended December 31, 2025, compared to $2.9 million for 2024, primarily due to goodwill impairment in the Nurse and Allied and Physician Staffing segments [195][199]. - The company recorded total unrecognized tax benefits of $10.4 million as of December 31, 2025 [241]. - A valuation allowance of $29.7 million was recorded on deferred tax assets as of December 31, 2025, with an additional $29.5 million recorded in Q4 2025 [240]. Operational Metrics - Total days filled decreased by 14.0% to 84,213 for the year ended December 31, 2025, compared to 97,888 for 2024 [206]. - Average revenue per day filled for Physician Staffing increased by $245, or 12.1%, to $2,274 for the year ended December 31, 2025 [206]. Claims and Reserves - The company had accrued $3.0 million and $4.8 million for incurred but not reported health insurance claims as of December 31, 2025 and 2024, respectively [228]. - As of December 31, 2025, the company had $12.0 million and $12.8 million accrued for case reserves and incurred but not reported workers' compensation claims, net of insurance receivables, for 2025 and 2024, respectively [228]. - The estimated amounts that had been worked but not billed totaled $48.3 million and $60.4 million as of December 31, 2025 and 2024, respectively [231]. - Total allowances for credit losses were $9.1 million and $9.3 million as of December 31, 2025 and 2024, respectively [234]. - The company maintains accruals for health, workers' compensation, and professional liability claims based on actuarial models reviewed semi-annually [228]. Interest and Currency Risks - Interest income increased to $3.1 million for the year ended December 31, 2025, up from $2.1 million in 2024, driven by higher average cash on hand [196]. - The company is exposed to variable interest rate risk from a Loan Agreement initiated on October 25, 2019, with a Term Loan Agreement repaid and terminated on June 30, 2023 [248]. - A 1% change in interest rates would have resulted in an immaterial fluctuation in interest expense for the years ended December 31, 2025 and 2024 [249]. - Approximately 5% of selling, general, and administrative expenses are related to software development and IT support from employees in Pune, India, indicating minor foreign currency risk exposure [250]. - Fluctuations in foreign currency exchange rates impact the translation of foreign-denominated assets and liabilities into U.S. dollars, affecting reported results [251]. - The translation of non-U.S. subsidiaries' assets and liabilities into U.S. dollars at the end of reporting periods affects stockholders' equity through accumulated other comprehensive loss [252]. Inflation Impact - Inflation did not significantly impact the company's operational results, and it aims to adjust billing rates to reflect cost increases due to inflation [247].

Core Insights - Cross Country Healthcare (CCRN) reported a revenue of $236.76 million for the quarter ended December 2025, reflecting a year-over-year decline of 23.6% [1] - The earnings per share (EPS) for the same period was -$0.06, compared to $0.04 a year ago, indicating a significant drop [1] - The reported revenue was 6.14% lower than the Zacks Consensus Estimate of $252.25 million, and the EPS surprise was -300% against the consensus estimate of $0.03 [1] Financial Performance Metrics - Cross Country's shares returned -0.2% over the past month, while the Zacks S&P 500 composite experienced a -1.3% change, suggesting relative stability [3] - The company holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3] Staffing and Revenue Data - Nurse and allied staffing reported 6,318 full-time equivalents (FTEs), which was below the estimated average of 6,535 by two analysts [4] - Physician staffing revenue per day filled was $2,286.00, exceeding the estimated average of $2,053.50 by two analysts [4] - Days filled in hours (HRS) for physician staffing were 18,599, surpassing the average estimate of 16,832 [4] - Revenue from physician staffing was $42.52 million, which was lower than the estimated average of $49.66 million by three analysts, representing a year-over-year decline of 19.8% [4] - Revenue from nurse and allied staffing was $194.24 million, below the estimated average of $203.75 million by three analysts, reflecting a year-over-year change of -24.4% [4]

Company Performance - Cross Country Healthcare (CCRN) reported a quarterly loss of $0.06 per share, missing the Zacks Consensus Estimate of $0.03, compared to earnings of $0.04 per share a year ago [1] - The earnings surprise for this quarter was -300.00%, and the company has only surpassed consensus EPS estimates once in the last four quarters [2] - Revenues for the quarter were $236.76 million, missing the Zacks Consensus Estimate by 6.14%, and down from $309.94 million year-over-year [3] Stock Movement and Outlook - Cross Country shares have increased by approximately 10.9% since the beginning of the year, while the S&P 500 has declined by 0.4% [4] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates of $0.02 for the coming quarter and $0.14 for the current fiscal year [8] Industry Context - The Staffing Firms industry, to which Cross Country belongs, is currently ranked in the bottom 9% of over 250 Zacks industries, indicating potential challenges ahead [9] - The performance of Cross Country's stock may be influenced by the overall industry outlook, as top-ranked industries tend to outperform the bottom-ranked ones significantly [9]

Core Viewpoint - Cross Country Healthcare is experiencing a stabilization in the healthcare staffing market, particularly in travel staffing, with expectations for growth in 2026 despite a challenging 2025 due to a terminated merger [3][2]. Financial Performance - Q4 revenue was $237 million, down 24% year-over-year, and full-year revenue was $1.05 billion, down 22% [5][7]. - Adjusted EBITDA for Q4 was $4 million, with a full-year adjusted EBITDA of $27 million, reflecting margins of 1.7% and 2.5% respectively [9][5]. - The company recorded a $78 million non-cash impairment charge related to the terminated merger, impacting below-EBITDA results [10][5]. Market Outlook - The company expects travel staffing to be flat to slightly up sequentially, with Travelers On Assignment projected to grow each month into Q2 [2][6]. - Management anticipates a revenue run rate exceeding $1 billion by the end of 2026, with an adjusted EBITDA margin of 4% to 5% [4][22]. Operational Strategy - The company is focusing on technology and operational efficiency, with plans to expand its workforce intelligence platform, Intellify, into new staffing markets [16][17]. - Cross Country Healthcare aims to enhance recruiter productivity and back-office efficiency through automation and AI initiatives [17][18]. Segment Performance - Travel staffing revenue declined 30% year-over-year, while home-based staffing grew 34% year-over-year, indicating a shift in demand [11][14]. - Education staffing revenue increased 48% sequentially, with expectations for growth in 2026 [13][12]. Balance Sheet and Shareholder Actions - The company ended the quarter with $109 million in cash and no debt, having repurchased over 1.3 million shares recently [4][19]. - Management believes the stock does not reflect its underlying value and anticipates further share repurchases [20].

Financial Data and Key Metrics Changes - Consolidated revenue for Q4 2025 was $237 million, down 5% sequentially and 24% year-over-year. Full-year revenue was $1.05 billion, down 22% from the prior year [15][16] - Gross profit for the quarter was $48 million, representing a gross margin of 20.3%, down 10 basis points sequentially but up 30 basis points year-over-year [16] - Adjusted EBITDA was $40 million for the quarter, with a margin of 1.7%, and $27 million for the full year, with a margin of 2.5% [18] Business Line Data and Key Metrics Changes - Nurse and Allied reported revenue of $194 million for the quarter, down 4% sequentially and 24% year-over-year. Travel Nurse revenue was down 9% sequentially and 30% year-over-year [21] - Home-based staffing revenue was $34 million in Q4, up 34% year-over-year, with continued growth anticipated [23] - Education staffing revenue was $18 million, up 48% sequentially but down 7% year-over-year [22] Market Data and Key Metrics Changes - The healthcare staffing market is stabilizing, with demand and bill rates showing signs of improvement. The number of Travelers On Assignment is expected to grow each month into Q2 2026 [7][21] - The company anticipates a flat to slightly up sequential growth in travel staffing for the first time in over three years [7] Company Strategy and Development Direction - The company aims to expand market share within large health systems, improve operational efficiency, and leverage technology as a differentiator [6][10] - A focus on operational rigor, technology-powered workforce solutions, and disciplined capital allocation is central to the company's strategy for long-term shareholder value [5][6] - The company plans to expand its proprietary technology portfolio, including Intellify, into adjacent sectors such as home-based and education staffing [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to revenue and earnings growth by the end of 2026, supported by a strong balance sheet and cash position [6][12] - The company is optimistic about the stabilization of the market and expects to see sequential growth across all lines of business throughout 2026 [30][64] Other Important Information - The company ended Q4 with $109 million in cash and no outstanding debt, positioning it well for strategic investments and capital allocation [24] - The company has repurchased over 800,000 shares in December and continued to buy back shares in Q1 2026, indicating confidence in its stock value [24] Q&A Session Summary Question: What is the confidence in achieving the revenue run rate above $1 billion and EBITDA margins of 4%-5%? - Management expressed high confidence due to a large sales pipeline, market-leading technology, and a strong balance sheet [30][32] Question: What are the opportunities for M&A in the current market? - The company is focused on strategic acquisitions in home-based staffing and is looking for accretive tuck-in acquisitions while being patient in capital allocation [36][37] Question: How is the technology platform Intellify being expanded into other markets? - The company plans to expand Intellify into home care and education staffing markets in 2026, with a strategy to provide solutions across the continuum of care [41][42] Question: What impact has labor disruption had on the business? - The company has participated in labor disruption events but noted that it is not a core business and the impact has been minimal [45][46] Question: What is the outlook for sequential revenue growth throughout 2026? - Management expects sequential growth across all quarters, with a target for year-over-year growth in the back half of 2026 [63][64]

Financial Data and Key Metrics Changes - Consolidated revenue for Q4 2025 was $237 million, down 5% sequentially and 24% year-over-year. Full-year revenue was $1.05 billion, down 22% from the prior year [15][16] - Gross profit for the quarter was $48 million, representing a gross margin of 20.3%, down 10 basis points sequentially but up 30 basis points year-over-year [16] - Adjusted EBITDA was $40 million for the quarter, with a margin of 1.7%, and $27 million for the full year, with a margin of 2.5% [18] Business Line Data and Key Metrics Changes - Nurse and Allied reported revenue of $194 million for the quarter, down 4% sequentially and 24% year-over-year. Travel Nurse revenue was down 9% sequentially and 30% year-over-year [21] - Home-based staffing revenue was $34 million in Q4, up 34% year-over-year, with continued growth anticipated due to an aging population [23] - Education staffing revenue was $18 million, up 48% sequentially but down 7% year-over-year, with expectations for growth in 2026 [22] Market Data and Key Metrics Changes - The healthcare staffing market is stabilizing, with demand and bill rates showing signs of improvement. The number of Travelers On Assignment is expected to grow each month into Q2 2026 [7][21] - The company anticipates a flat to slightly up sequential growth in travel staffing for the first time in over three years [7] Company Strategy and Development Direction - The company aims to restore momentum and sharpen execution, focusing on expanding market share within large health systems and leveraging technology as a differentiator [5][6] - A disciplined capital allocation strategy is in place, with plans for strategic investments and share repurchases to enhance shareholder value [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to revenue and earnings growth by the end of 2026, supported by a strong balance sheet and cash position [6][12] - The company is optimistic about the stabilization of the market and expects to see sequential growth across all business lines throughout 2026 [50][66] Other Important Information - The company ended Q4 2025 with $109 million in cash and no outstanding debt, positioning it well for strategic investments [24] - The company has made significant investments in revenue producers, which are already yielding positive results [11] Q&A Session Summary Question: What is the confidence level in achieving the revenue run rate above $1 billion and EBITDA margins of 4%-5%? - Management expressed high confidence due to a strong sales pipeline, market-leading technology, and a solid balance sheet [30] Question: What needs to happen to achieve the higher margin levels by the end of the year? - Management indicated that operating leverage and a better mix of higher-margin businesses will contribute to margin improvement [33] Question: What opportunities do you see for M&A in the current market? - The company is focused on strategic acquisitions in high-growth areas like home-based staffing and is being patient in its capital allocation strategy [36] Question: Can you provide details on the expansion of the Intellify platform into other markets? - The company plans to expand Intellify into home-based and education staffing markets in 2026, with a focus on providing comprehensive solutions across all divisions [41][42] Question: How is the Center of Excellence in India contributing to cost savings? - The Center has reduced headcount and moved many business processes offshore, resulting in significant operational leverage and efficiency improvements [68]

Financial Data and Key Metrics Changes - Consolidated revenue for Q4 2025 was $237 million, down 5% sequentially and 24% year-over-year. Full-year revenue was $1.05 billion, down 22% from the prior year [13][14] - Gross profit for the quarter was $48 million, representing a gross margin of 20.3%, down 10 basis points sequentially but up 30 basis points year-over-year [15] - Adjusted EBITDA was $40 million for the quarter, with a margin of 1.7%, and $27 million for the full year, with a margin of 2.5% [17] Business Line Data and Key Metrics Changes - Nurse and Allied reported revenue of $194 million for the quarter, down 4% sequentially and 24% year-over-year. Travel Nurse revenue was down 9% sequentially and 30% year-over-year [20] - Home-based staffing revenue was $34 million in Q4, up 34% year-over-year, with continued growth anticipated [23] - Education staffing revenue was $18 million, up 48% sequentially but down 7% year-over-year, with expectations for growth in 2026 [21][22] Market Data and Key Metrics Changes - The healthcare staffing market is stabilizing, with demand and bill rates showing signs of improvement. The number of Travelers On Assignment is expected to grow each month into Q2 2026 [6][20] - The company anticipates a flat to slightly up sequential growth in travel staffing for the first time in over three years [6] Company Strategy and Development Direction - The company aims to expand market share within large health systems, improve operational efficiency, and leverage technology as a differentiator [5] - A focus on operational rigor, technology-powered workforce solutions, and disciplined capital allocation is central to the company's strategy for long-term shareholder value [4] - The company plans to expand its proprietary technology portfolio, particularly the Intellify platform, into adjacent markets such as home-based and education staffing [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to revenue and earnings growth by the end of 2026, supported by a strong balance sheet and cash position [5][11] - The company is optimistic about the stabilization of the market and the potential for growth in various business lines, particularly travel and home-based staffing [6][32] Other Important Information - The company ended Q4 with $109 million in cash and no outstanding debt, positioning it well for strategic investments and share repurchases [24] - The company has made significant investments in revenue producers, which are expected to drive organic growth throughout 2026 [10][17] Q&A Session Summary Question: What is the confidence in achieving the revenue run rate above $1 billion and 4%-5% EBITDA margins by the end of 2026? - Management expressed high confidence due to a strong sales pipeline, market-leading technology, and a solid balance sheet [31][32] Question: What are the opportunities for M&A in the current market? - The company is focused on disciplined capital allocation and is exploring accretive tuck-in acquisitions, particularly in home-based staffing [39] Question: How is the technology platform Intellify being expanded into other markets? - The company plans to expand Intellify into home care and education staffing markets in 2026, with a strategy to provide solutions across the continuum of care [43][44] Question: What impact has labor disruption had on the business? - The company has participated in labor disruption events but noted that it is not a core business and the impact has been minimal [46][48] Question: What is the outlook for sequential revenue growth throughout 2026? - Management expects sequential growth across all quarters, with a target for year-over-year growth in the back half of the year [65][66]

Revenue Performance - Fourth quarter revenue was $236.8 million, a decrease of 24% year-over-year and 5% sequentially [6]. - Full year revenue for 2025 was $1.1 billion, down 22% compared to 2024 [8]. - Revenue from services for the three months ended December 31, 2025, was $236,761,000, a decrease from $309,940,000 for the same period in 2024, representing a decline of approximately 23.6% [27]. - For the year ended December 31, 2025, total revenue was $1.05 billion, a decline of 22% from $1.34 billion in 2024 [33]. - Revenue from services for Q4 2025 was $236.76 million, a decrease of 24% year-over-year from $309.94 million in Q4 2024 [33]. Financial Losses - Net loss attributable to common stockholders for Q4 2025 was $82.9 million, compared to a net loss of $3.8 million in Q4 2024 [6]. - The net loss attributable to common stockholders for the three months ended December 31, 2025, was $82,929,000, compared to a loss of $3,753,000 in the same period of 2024, reflecting a significant increase in losses [27]. - The net loss per share attributable to common stockholders for the year ended December 31, 2025, was $2.93, compared to $0.44 in 2024, indicating a worsening financial position [27]. - Loss from operations for Q4 2025 was $(71.61) million, compared to a loss of $(3.43) million in Q4 2024 [33]. Adjusted EBITDA and Profitability - Adjusted EBITDA for Q4 2025 was $4.1 million, representing 1.7% of revenue, down from $9.3 million or 3.0% of revenue in Q4 2024 [7]. - Adjusted EBITDA for the year ended December 31, 2025, was $26,801 thousand, with an adjusted EBITDA margin of 2.5%, down from 3.7% in 2024 [29]. - Contribution income for Q4 2025 was $15.86 million, down 34% from $23.90 million in Q4 2024 [33]. Cash Flow and Assets - Cash flows from operations for Q4 2025 were $18.2 million, a decrease of 25% year-over-year [10]. - The company had $109 million in cash on hand and no debt as of December 31, 2025 [5]. - Cash and cash equivalents increased to $108,738 thousand in 2025, up from $81,633 thousand in 2024 [31]. - Total current assets decreased to $293,589 thousand as of December 31, 2025, from $335,000 thousand in 2024 [31]. Operating Expenses - Total operating expenses for the year ended December 31, 2025, were $1,138,707,000, down from $1,360,869,000 in 2024, indicating a reduction of about 16.3% [27]. - Direct operating expenses for the three months ended December 31, 2025, were $188,779,000, down from $247,948,000 in 2024, a decrease of approximately 23.9% [27]. - Corporate overhead for Q4 2025 was $19.49 million, an increase of 13% from $17.25 million in Q4 2024 [33]. Impairment Charges - The company reported impairment charges of $77,851,000 for the year ended December 31, 2025, compared to $2,888,000 in 2024, highlighting significant asset write-downs [27]. - Impairment charges for Q4 2025 were $77.85 million, significantly higher than $2.17 million in Q4 2024 [33]. - Impairment charges for the year totaled $77,851 thousand, reflecting ongoing challenges in asset valuation [29]. Shareholder Information - The company repurchased over 800,000 shares, or 2.5% of common stock outstanding, in Q4 2025 [5]. - The weighted average common shares outstanding for the year ended December 31, 2025, were 32,409,000, a slight decrease from 33,379,000 in 2024 [27]. - The weighted average common shares outstanding for diluted EPS were 32,411 thousand for the year ended December 31, 2025 [29]. Future Guidance and Risks - The guidance for Q1 2026 projects revenue between $235 million and $240 million, reflecting a year-over-year decline of 20% to 18% [15]. - The company aims to exit 2026 with a revenue run-rate exceeding $1 billion and a profit margin between 4% and 5% [4]. - The company expects to face inherent risks and uncertainties that could materially affect future performance, including economic changes and regulatory impacts [23]. - The company does not assume any obligation to update or revise forward-looking statements made in its press releases [24].

Company Insights - Arrow Electronics is one of the world's largest distributors of electronic components and enterprise computing products, with a projected 3-5 year EPS growth rate of 15.2% and a Zacks Rank 1 (Strong Buy) [6][8] - Arrow's recent partnerships, including collaboration with .lumen for AI-powered assistive technology, highlight its innovation leadership and are expected to bolster future growth [7] - Gold.com operates as a fully integrated alternative assets platform, with a stock price that has surged 83% over the past three months and an expected earnings growth rate of 63.1% for the current year, also holding a Zacks Rank 1 [9][10] - Cross Country Healthcare provides talent management and consultative services for healthcare clients, benefiting from strong relationships and momentum in home care and physician staffing, currently holding a Zacks Rank 3 (Hold) [11][12] - AMN Healthcare Services has evolved into a strategic total talent solutions partner, with a unique MSP that streamlines workforce planning and improves patient care, also holding a Zacks Rank 3 [13][14] - PENN Entertainment is recognized for consistent strategy execution and strong brand recognition, with earnings surpassing the Zacks Consensus Estimate in three of the last four quarters, currently holding a Zacks Rank 3 [15] Market Trends - The technology sector has experienced a sharp downturn due to investor concerns regarding the sustainability of the AI trade and elevated valuations of AI stocks, alongside sell-offs in cryptocurrencies like Bitcoin [2] - Despite market volatility, investors are encouraged to consider broker-favored stocks, indicating potential investment opportunities in the current environment [3]